MRX-2843 is also being advanced in multiple phase I trials, including studies in (1) adults with relapsed/refractory advanced and/or metastatic solid tumors (NCT03510104), (2) adolescents and adults with relapsed/refractory acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), or mixed-phenotype acute leukemia (NCT04872478), and (3) combined with Osimertinib for treatment of advanced EGFR mutant non-small cell lung cancer (NCT04762199). This evidence concerns the gene EGFR and acute myeloid leukemia.